Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice

• Autori principali: Henry L. Blanton (Autore), Melissa C. McHann (Autore), Haley De Selle (Autore), Canice Lei Dancel (Autore), Jose-Luis Redondo (Autore), Deborah Molehin (Autore), Nadezhda A. German (Autore), Scott Trasti (Autore), Kevin Pruitt (Autore), Isabel Castro-Piedras (Autore), Josée Guindon (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Cannabinoid-based therapies are increasingly being used by cancer patients to treat chemotherapy-induced nausea and vomiting. Recently, cannabinoids have gained increased attention for their effects on cancer growth. Indeed, the effect of CB2 (JWH-015, JWH-133) agonists on breast cancer models have...